CD38 blockade either as a single agent or in combination with anti-PD-L1 did not suppress the tumor growth in the immune competent-mouse subcutaneous RPP model as compared to vehicle control or anti-PD-L1 treatment (Figure 2D). The gene discussed is CD38; the disease is neoplasm.